On 19th November 2026, the UK government confirmed it will rewrite the legal definition of a gene therapy medicinal product (GTMP).
For most companies, this will read as a technical tidy-up. For some, it changes which regulatory framework their product sits in.
If you develop synthetic nucleic acid therapies, genome editing products or engineered cell therapies, the MHRA gene therapy definition is no longer an academic point. Classification decides your regulatory route, shapes your CMC expectations and affects who can manufacture your product.
Here is what has been confirmed, what has not, and what to do about it now.
Key takeaways
• The UK will define gene therapies by how they work, not by whether they are biological in origin.
• A product will be a GTMP if it contains recombinant or synthetic nucleic acid that is transcribed or translated, or if its mechanism involves deliberate, sequence-specific genome editing.
• Vaccines against infectious diseases stay excluded. Antisense oligonucleotides and siRNAs are not being reclassified.
• Medicines that are already licensed will not need to be reclassified.
• Nothing changes yet. The amendments still need secondary legislation, international notification and parliamentary approval, and no dates have been published.
What the MHRA announced
The announcement follows a consultation run by the MHRA jointly with the Department of Health in Northern Ireland between 11 May and 22 June 2026. The government response reports that 40 of the 48 respondents, or 83%, supported the proposals.
The current definition sits in Regulation 2A of the Human Medicines Regulations 2012 and traces back to a framework developed in 2007. It assumes a GTMP is a biological medicinal product built on recombinant nucleic acids, with a therapeutic effect that comes directly from that sequence or what it expresses.
That worked when most gene therapies were viral vectors. It fits less comfortably with synthetic mRNA, chemically manufactured DNA and genome editors delivered as proteins or synthetic RNA rather than as recombinant genetic material. The MHRA's concern was that this mismatch creates uncertainty over classification, inconsistent oversight and barriers for developers.
The government now intends to amend Regulation 2A through secondary legislation, taking a technologically neutral approach.
The new gene therapy definition in plain terms
Under the revised approach, a product becomes a GTMP through one of two routes.
1. Expression. The product contains recombinant or synthetic nucleic acid that is transcribed or translated. Whether that nucleic acid was made in a cell or on a synthesiser no longer decides the question.
2. Genome editing. The product's mechanism of action involves deliberate, sequence-specific editing of the genome, whatever type of substance delivers the edit. Cells modified in this way are also captured.
The consultation also proposed that the nucleic acid would no longer need to be directly responsible for the therapeutic effect, and that a GTMP would no longer need to act directly on human cells. The first point matters for engineered cell therapies, where genetic modification often supports persistence, manufacturing or safety rather than delivering the treatment itself.
What sits outside the definition
What the change leaves alone matters just as much.
Vaccines against infectious diseases remain excluded. That exclusion does not extend to individualised mRNA cancer immunotherapies that otherwise meet the criteria.
Antisense oligonucleotides and siRNAs are not being reclassified. They are not transcribed or translated, so they fall outside the expression route. The consultation took the same position on saRNAs, microRNAs and unmodified bacteriophages and oncolytic viruses.
Epigenetic or epitranscriptomic modulation on its own is not included. The MHRA will monitor that field and may issue further classification guidance.
The government also declined to adopt an EU-style "long-lasting" expression criterion. That is a deliberate point of difference, and it has consequences for anyone developing for both markets.
Not sure which side of the line your product falls? TDP's CMC and regulatory affairs team can assess your products against the new definition and set out what classification means for your development plan.
Talk to our regulatory team - request a call back
What GTMP classification means for pharma and biotech companies
Classification is more than a label. It determines the regulatory framework, and the framework shapes almost every decision that follows.
The government response is clear that falling within the advanced therapy framework does not imply identical regulatory requirements. Expectations remain risk-based and proportionate. Even so, a change of category raises practical questions in four areas.
1. Regulatory strategy. Development plans, scientific advice and submission strategy built on a non-ATMP assumption will need revisiting if a product moves into the GTMP category.
2. CMC and quality. The MHRA's consultation suggested developers should follow the most appropriate chemical or biological guidance case by case, using a risk-based approach. A synthetic product will not automatically be treated like a viral vector. Your CMC narrative will need to show why the controls you have chosen are the right ones.
3. Manufacturing and supply chain. If a contract manufacturer makes your product, check that its authorisations and quality system cover advanced therapy products. A partner well set up for synthetic oligonucleotides may not be set up for ATMPs.
4. Investment and transactions. For investors and acquirers, classification is now a due diligence question. A lead asset that may change category carries regulatory and timeline uncertainty that should be understood before the deal is priced.
Illustrative example (hypothetical, not a TDP client case)
A biotech is developing a lipid nanoparticle delivered synthetic mRNA that makes a missing enzyme in a rare metabolic disease. Today, the synthetic origin of that mRNA means its fit with the existing GTMP wording is open to debate.
Under the new definition, a synthetic nucleic acid that is translated falls squarely within the expression route. The sensible move is to plan on GTMP classification, revisit the CMC strategy and confirm early that the chosen manufacturer can support an advanced therapy product.
What has not changed
The government has stated that existing processes for assessing and approving medicines are unchanged, that safety, quality and efficacy standards continue to apply, and that medicines already licensed will not need to be reclassified.
Nothing is in force yet either. The MHRA will progress the legislative changes subject to international notification procedures and parliamentary approval. No implementation date has been published, and transition arrangements for products already in development have not been set out.
That gap is where the planning risk sits. Licensed products are protected. Products in development are where classification questions will land first.
Practical steps to take now
1. Map your portfolio against the two routes. For each product, ask two questions. Does it contain nucleic acid that is transcribed or translated? Does its mechanism involve deliberate, sequence-specific genome editing? Record the answer and the reasoning.
2. Prioritise development-stage products. Products in clinical development, or close to it, carry the most exposure. Check how a change of category would affect your clinical trial plans, investigational product manufacturing and future submissions.
3. Review your manufacturing arrangements. Confirm what your CDMO is authorised for and how its quality system handles advanced therapy products. Raise it now rather than at technology transfer.
4. Plan for divergence between markets. UK classification may not match EU or US treatment, particularly for synthetic nucleic acids, non-viral delivery and novel editing approaches. Build a jurisdiction-by-jurisdiction view rather than assuming one answer applies everywhere.
5. Engage early and watch the detail. The MHRA has said it will consider guidance to support implementation. Track the statutory instrument when it is laid, check the final wording against your assessment, and seek regulatory advice early where your product sits near the boundary.
Need a clear classification view before the legislation lands? TDP can review your portfolio, test the reasoning and build the change into your regulatory and CMC plans.
Frequently asked questions
-
No. The government confirmed its intention on 19 November 2026, but the change requires secondary legislation, international notification procedures and parliamentary approval. No implementation date has been published.
-
No. Vaccines against infectious diseases remain excluded. Individualised mRNA cancer immunotherapies are not covered by that exclusion and can fall within the definition if they meet the criteria.
-
No. They are not transcribed or translated, so they sit outside the expression route, and the government has confirmed they are not being reclassified.
-
No. The government has stated that medicines already licensed will not need to be reclassified.
-
Not necessarily. The government response states that classification within the advanced therapy framework does not imply identical regulatory requirements, and expectations remain risk-based and proportionate.
The bottom line
Defining gene therapy by mechanism rather than origin is a sensible move, and most of the industry agreed. It brings certainty to products that currently sit in a grey area.
Certainty only helps if you act on it. The companies that benefit will be the ones that have assessed their portfolio, aligned their manufacturing and adjusted their regulatory plans before the legislation arrives.
If you want a clear, practical view of where your products stand, talk to TDP.